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series adequately captured the pattern in the data and
showed increasing tendency of HCV seropositivity with
-1
-1
a mean ± SD HCV seroprevalence (1000 × month )
of 24.3 ± 1.4 over the forecast interval.
CONCLUSION: To curtail HCV spread, public health
authorities need to educate communities and health
care providers about HCV transmission routes based
on known HCV epidemiology in Pakistan and its
neighboring countries. Future research may focus on
factors associated with hyperendemic levels of HCV
infection.
© 2009 The WJG Press and Baishideng. All rights reserved.
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Abstract
AIM: To identify the stochastic autoregressive
integrated moving average (ARIMA) model for short
term forecasting of hepatitis C virus (HCV) seropositivity
among volunteer blood donors in Karachi, Pakistan.
METHODS: Ninety-six months (1998-2005) data on
-1
-1
HCV seropositive cases (1000 × month ) among male
volunteer blood donors tested at four major blood
banks in Karachi, Pakistan were subjected to ARIMA
modeling. Subsequently, a fitted ARIMA model was
used to forecast HCV seropositive donors for 91-96 mo
to contrast with observed series of the same months.
To assess the forecast accuracy, the mean absolute
error rate (%) between the observed and predicted
HCV seroprevalence was calculated. Finally, a fitted
ARIMA model was used for short-term forecasts
beyond the observed series.
RESULTS: The goodness-of-fit test of the optimum
A R I M A ( 2 , 1 ,7 ) m o d e l s h o w e d n o n - s i g n i f i c a n t
autocorrelations in the residuals of the model. The
forecasts by ARIMA for 91-96 mo closely followed the
pattern of observed series for the same months, with
mean monthly absolute forecast errors (%) over 6 mo
of 6.5%. The short-term forecasts beyond the observed
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INTRODUCTION
Hepatitis C virus (HCV) infection poses a major public
health problem in developing countries, including
Pakistan. However, the results of prevalence studies have
shown variable estimates in select groups including 1.8%
to 3.0% in volunteer blood donors[1,2] and 16% to 20.5%
in familial contacts of infected patients[3,4]. A communitybased study in Hafizabad, Punjab, found a 6.5% HCV
seroprevalence[5]. Using these estimates, Pakistan has
been grouped into intermediate category with respect
to burden of HCV infection[6]. Several routes have been
implicated for nosocomial and community acquired
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HCV infection including unsafe injections, recycling of
used syringes, inadequate sterilization of surgical and
dental equipment, and facial shaving by barbers[2,7].
Public health authorities in Pakistan intermittently
run educational campaigns in electronic and print media
to create awareness in the general population to halt
HCV spread. However, in the absence of adequate
HCV surveillance, the true impact of the HCV control
efforts remains uncertain. Volunteer blood donors are
generally considered to be the healthier segment of any
community and the proportions of HCV seropositivity
among them may be considered to mirror the situation
in the general population[8]. We have previously reported
a significant increase in HCV seroprevalence among
volunteer blood donors over the past several years using
data from two blood banks[2]. However, there is need to
expand this HCV surveillance network countrywide to
obtain more reliable and representative estimates.
Recently, mathematical models have been used to
project the future HCV prevalence among intravenous
drug users[9], and its impact on the future development
of HCV related morbidity and mortality[10]. Modeling
and forecasting HCV seropositivity among volunteer
blood donors in Pakistan, and perhaps in other
neighboring countries, might provide useful information
for allocating resources, and re-shaping and planning
future control activities[11]. This study aimed to develop
a univariate time series model for HCV seropositivity
(1000 -1 × month -1 ) among volunteer blood donors
attending four large blood banks. Specifically, the
objective of this study was to identify the stochastic
autoregressive integrated moving average (ARIMA)
model for short term forecasting of HCV seropositivity
(1000-1 × month-1) among volunteer blood donors in
Karachi, Pakistan.

MATERIALS AND METHODS
Setting
This study was conducted in Karachi-the largest
cosmopolitan city and the hub of economic activity
of Pakistan. It has an estimated population of 9.3
million, accounting for approximately 10% of the total
population of the country. Forty three percent of the city’
s population is under the age of 15 years. The population
of Karachi comprises several ethnic groups defined by
mother tongue, including predominantly Urdu, Sindhi,
Punjabi, Pushto, and Balochi. The healthcare facilitates
for the population include several small and tertiary care
hospitals, both in the private and public sector.
Data
Eight-year (1998-2005) data on monthly aggregates of
number of donors attending four large blood banks
(blood bank Ⅰ-Ⅳ) in Karachi were available for this
study. These blood banks receive blood donations only
from non-remunerated volunteer blood donors. Blood
bank Ⅰ is part of a tertiary care hospital in the private
sector and receives blood donations as replacements
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from friends and relatives of inpatients requiring
blood transfusions. Blood banks Ⅱ-Ⅳ belong to nongovernmental organizations and cater for the needs of
those in Karachi who need blood transfusions, including
the patients with leukemia, hemophilia, thalassemia and
other blood related diseases. Blood banks Ⅱ-Ⅳ also
receive blood donations from volunteers on an exchange
basis. Prior to blood donation, each blood donor
is subjected to screening for known risk factors for
transfusion transmissible infections. All the blood banks
follow similar criteria to receive blood donations and
exclude potential donors who admit known risk factors
of transfusion transmissible infections or any medical
or non-medical condition associated with high risk (e.g.
use of narcotic drugs, history of jaundice in the past
5 years and recent hospitalization). All four blood banks
in the study use commercially available enzyme-linked
immunosorbant assay kits and results are interpreted
according to the manufacturer’s instructions.
As noted earlier, blood donations between January
1998 and December 2005 by men aged 18-64 years were
included in this evaluation. HCV serological results of
consecutive blood donations from these blood banks
were available from variable starting dates depending
on the completed records, to assess the proportions of
HCV seropositive donors.
Analytic approach
We used methods developed by Box and Jenkins to build
an ARIMA time series model[12]. This model-building
process is designed to take advantage of associations in
the sequentially lagged relationships that usually exist
in data collected periodically. The general form of the
ARIMA model was
∆1zt = Φ1 zt - 1 + … + Φp zt - p + at - θ1at - 1 - … - θqat - q
where:
∆1zt = differenced series i.e. zt - zt - 1
zt = set of possible observations on the time-sequenced
random variable
at = random shock term at time t
Φ1 … ΦP = autoregressive parameters of order p
θ1 … θp = moving average parameters of order q
The series was subjected to Box-Cox transformation[13].
The transformed series was then differenced at the nonseasonal level and mean corrected to induce stationarity.
Sample autocorrelation and partial autocorrelation
functions were used to identify the ARIMA model
of the appropriate order. Estimates of the model’s
parameters were obtained by the maximum likelihood
method. Diagnostic checking included residual analysis
and the Akaike Information Criterion was used to
compare goodness-of-fit among ARIMA models. The
final model was a result of several iterations of the
identification, estimation, and checking process, and
met the conventional criteria for the adequacy of the
model[14].
Assessment of forecast accuracy
The last 6 observations in the data set were used for
validation of the forecast accuracy of the ARIMA
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Figure 1 Hepatitis C virus seroprevalence (1000-1 × month-1) among volunteer male blood donors in Karachi, Pakistan 1998-2005. A: Observed data along
with forecasts; B: Transformed series.
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Table 1 Hepatitis C virus seroprevalence (1000 × year )
among male volunteer blood donors at four large blood banks
in Karachi (1998- 2005)
Yr

Mean

SD

13.8
16.3
18.5
19.8
19.9
20.3
29.3
24.8
20.3

1.5
2.2
2.2
2.0
3.0
3.2
2.6
2.1
5.1

1998
1999
2000
2001
2002
2003
2004
2005
Total

95% CI for mean
Minimum Maximum
Lower limit Upper limit
12.8
14.8
17.1
18.6
18.0
18.2
27.6
23.4
19.3

14.7
17.7
19.9
21.1
21.8
22.3
30.9
26.1
21.3

12
13
15
16
15
16
25
21
12

16
21
22
22
26
27
33
27
33

F = 47.9; df = 7, 88; P < 0.001.

model. The fitted ARIMA model was used to forecast
the HCV seroprevalence (1000-1 × month-1) for 91-96
mo (June 2005 to December 2005) to contrast with
the observed series of the same months. The average
forecast error at prediction interval of m months (em) was
calculated as:
(em) = [ ∑( yt = m - yˆ t = m )/6]1/2
Where yt = m and yˆ t = m denote the observed and forecast values for month t + m. Finally, the fitted ARIMA model
was used for short term (January 2006 to June 2006)
forecasts along with their 95% confidence limits beyond
the observed series.
6

m =1

RESULTS
Descriptive analysis
The crude HCV seropositivity (1000-1) among the male
volunteer blood donors during the study period was
20.3 (12 792/630 134). The mean prevalence (1000 -1
× month -1) was 18.3 [95% confidence interval (CI):
16.8-19.9]. There was no statistically significant difference
in HCV seropositivity (1000-1) across various months
of the years (F = 0.201; P = 0.997) (data not shown).
However, a substantial variation in HCV seroprevalence
(1000-1) was observed across different calendar years
(F = 47.895; P < 0.001) (Table 1). The observed and
transformed series are presented in Figure 1.
ARIMA model
The parameters’ estimates for the optimum ARIMA
(2,1,7) model for the series of monthly HCV
seropositive donors (1000-1) are shown in Table 2. The
autocorrelation and partial autocorrelation functions of
the residuals showed good-fit (Figure 2). The residual
plots showed small variations around the zero mean.
None of these residuals had its magnitude larger than
twice the standard deviation. Residuals’ autocorrelations
were not significantly different from zero as a set and
had constant variance, thus confirming the adequacy of
the model (Ljung-Box statistic = 20.4; P = 0.433).
The forecasts by the ARIMA (2,1,7) model for
91-96 mo (June 2005 to December 2005) using the
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Table 2 Autoregressive integrated moving average model
-1
(2,1,7) of hepatitis C virus seroprevalence (1000 ×
-1
month ) among male volunteer donors in Karachi, Pakistan,
(January 1998-December 2005)

0.80

-0.20
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Residual PACF

Autoregressive parameter (Φ)
Φ2
Moving average parameter (θ)
θ2
θ3
θ4
θ6
θ7

Estimate

Standard error

t -ratio

0.67

0.15

4.5

-0.59
0.49
-0.80
0.74
-0.37

0.18
0.15
0.11
0.21
0.17

3.3
3.3
7.3
3.5
2.2

White noise variance = 9.74; Ljung-Box Q statistic = 20.4 (P = 0.433).
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Figure 2 Residual plots for the final ARIMA (2,1,7) model of HCV
seroprevalence (1000-1 × month-1) among male volunteer blood donors
in Karachi, Pakistan 1998-2005. A: Autocorrelation function; B: Partial
autocorrelation function.

obser ved series of months 1-90, closely followed
the pattern of observed series for the same months
(Figure 1), with mean ± SD and maximum monthly
absolute forecast errors (%) over 6 mo interval being
6.5% ± 3.4% and 10%, respectively. Furthermore,
the short term (January 2006 to June 2006) forecasts
beyond the observed series adequately captured the
pattern in the data (Figure 1) and showed evidence of
increasing tendency of HCV seroprevalence (1000-1 ×
month-1) with the mean ± SD as 24.3 ± 1.4 over the
forecast interval.

DISCUSSION
Epidemiological surveillance of communicable diseases
is one of the more traditional public health activities.
Time series analysis of surveillance data on prevalence
and/or incidence of various infections may be helpful
in developing hypotheses to explain and anticipate the
dynamics of the observed phenomena and subsequently
in the establishment of a quality control system and reallocation of resources[15,16]. This method is an ecologic
approach and takes advantage of the strong association
in the sequentially lagged relationship that usually exists
in the data collected periodically[17].
D u r i n g t h e s t u d y p e r i o d , t h e o ve r a l l H C V
seroprevalence (1000-1) in volunteer blood donors was
20.3, which falls in the range of 14.9 to 38.9 known for
first time blood donors in other developing countries.
However, HCV seroprevalence (1000 -1) in this study
was much higher than the 2.1 reported for developed
countries[18]. The low HCV seroprevalence in resource-

rich countries is attributed to safe blood transfusion,
whereas, in poor regions of the world, several million
people acquire HCV infection each year as a result of
contaminated transfusions and the re-use of infected
medical devices[18,19]. Therefore, public health practices
adopted by the developed countries need to be strictly
enforced in less developed countries to break the
chain of transmission of HCV and other blood-borne
pathogens.
Monitoring of HCV seropositivity among volunteer
blood donors may provide clues about the effectiveness
of control efforts of public health authorities and future
trend of the proportion of HCV infected donors in
Pakistan. In this paper, we used the ARIMA model on
a time series of HCV seropositivity (1000-1) collected
monthly over a period of 96 mo on asymptomatic male
volunteer blood donors from four major blood banks
in Karachi. The forecasts made in a prospective manner
over six months demonstrated increasing tendency of
HCV seropositivity among the blood donors in this
cosmopolitan city. Such a predicted increase in HCV
seropositivity might result from inconsistent and naïve
HCV control efforts on the part of public health
officials in Pakistan. Therapeutic injections in a healthcare setting have consistently been shown as a strong
risk factor for HCV infection in Pakistan[2,7,20,21], and if
concerted efforts by the public health authorities are not
made, might continue to contribute to the increasing
load of HCV infection in this and similar settings in the
region. An increasing trend among first time US blood
donors of 50 to 59 years of age from 1995 to 2002 has
been demonstrated[22]. According to the authors, teenage
children and young adults in 1960, and 1970s might have
experimented with drug injection and were infected with
HCV. These people entered into the 50 to 59 years age
group during 1995 to 2002. However, in other age groups
of donors in the same study and two other studies from
US[23,24], and from other developed countries (France[25,26]
and Spain[27]) have shown a decreasing trend of residual
risk of HCV infection in blood donors. According to
these investigators different factors could have played a
role in this reduction, for instance, increased awareness
about the factors associated with increased risk of
HCV infection, voluntary deferral by potential high risk
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donors, improvement in donor recruitment, and /or an
overall decrease in HCV infection level in the general
population. Such factors need to be evaluated in our
population in future studies.
Results from our previous study [2] , and those
predicted by ARIMA model for 6 mo beyond the
observed data exhibited a slightly increasing tendency of
HCV seropositivity among male volunteer blood donors
over the forecast period. This increasing pattern of
HCV seroprevalence among these asymptomatic male
volunteer donors merits further investigation of factors
contributing to HCV seroprevalence in this population,
which is thought to be a mirror image of the situation in
the general population.
Some limitations of this study need to be taken
into account when interpreting the results. Our HCV
seroprevalence estimates are based on ELISA, which has
sensitivity of more than 95%. However, these results
do not reflect possible HCV infections that do not
produce detectable seropositivity during the window
period of HCV infection. The exact proportion of these
HCV infected, but HCV seronegative, is not known,
however, it has been argued that this figure must be
very small given the use of current sero-assays[28]. Our
HCV seroprevalence estimates in male volunteer donor
population were based on data from a limited number of
blood banks; we do not know whether they reflect the
national average. The blood banks that participated in
this study however, account for a substantial proportion
of donations made annually in Karachi. These centers
are located in large metropolitan areas where the
prevalence and/or incidence of HCV may be higher than
the national figures. Therefore, we think we are justified
in making generalizations from our data. In conclusion,
in the absence of comprehensive HCV surveillance in
the general population in Pakistan and perhaps in other
neighboring countries, further monitoring of HCV
seropositivity in blood donors and the investigation of
factors associated with hyperendemic HCV infection
using multivariate ARMIA models might further expand
our understanding about HCV epidemiology in this
region. Furthermore, effective screening of all blood
donors for HCV infection at all blood banks should be
seriously considered, because one single HCV infected
regular blood donor could transmit the infection to
several recipients.

model that might be used to monitor and predict trends in hepatitis C virus (HCV)
seroprevalence in the general population using volunteer blood donors as a
sentinel group. This information may be helpful to facilitate early public health
responses to minimize HCV related morbidity and mortality.

Research frontiers

Developed countries have been able to control the HCV transmission in the
general population by public health measures. However, such initiatives are
practiced at sub-optimal level in resource-constrained countries. This problem is
further compounded by the absence of effective surveillance of communicable
diseases including blood-borne pathogens. Therefore, alternative methods
to monitor and predict the burden of such infections are needed for rational
allocation of resources.

Innovations and breakthroughs

This is the first application of an ARIMA model to monitor and predict the HCV
seroprevalence in volunteer blood donors at multiple blood banks. Such data on
infections with HCV and other blood-borne pathogens may mirror the situation
in a setting that lacks an effective surveillance system for these infections.

Application

The fitted ARIMA model could be used for sentinel surveillance of blood-borne
infections in volunteer blood donors. Therefore, the estimates for current and
predicted future burden of these infections could be used by public health
authorities for making rational policy decisions for control and prevention of
HCV and other blood-borne pathogens in resource-constrained countries
including Pakistan.

Peer review

The authors describe an effective model to predict HCV seropositivity in
Pakistan.
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